Last December, European regulators said they were no longer sure whether results from a trial of Bayer's new-age clot-buster Xarelto were accurate thanks to a defect in a blood-clotting testing device used in the study. But the German pharma can breathe easy now.
Bayer snapped up China's Dihon in 2014 with the idea of combining Dihon's traditional Chinese medicines with Bayer's Western OTC products in a major consumer health play in the country. Now it has a large new plant there to produce both kinds of products.
Bayer boosted the reach of its international consumer health business when it picked up Chinese herbal and OTC special Dihon in 2014. Now it has boosted its production capacity with a new plant that will manufacture both Western OTC products and traditional Chinese medicines.
In the do-well-by-doing-good category, pharma companies and their agency partners are stepping up their public health projects in the developing world, and they're spotlighting some of those efforts at the United Nations this week.
Panasonic Healthcare has closed its purchase of the Bayer Diabetes Care business for about $1.1 billion. The deal was originally disclosed in June and was funded in part by well-known hedge fund KKR, which holds 80% of Panasonic Healthcare with the remainder owned by the larger Panasonic corporate entity.
Bayer may have a big-time move up its sleeve, Reuters ' sources say--and it could include animal health leader Zoetis or Pfizer's consumer offerings.
Bayer knows it needs more M&A if it wants to keep up in the rapidly consolidating OTC and animal health businesses. But it's not just looking for bolt-on deals.
Bayer is making a $335 million wager on the future of gene editing. The pharma company has committed $300 million in research support to a new joint venture with CRISPR Therapeutics that will operate out of Cambridge, MA. And the biotech upstart is grabbing a $35 million equity investment from Bayer, which also signaled a big appetite for more life science deals.
The consumer health space is consolidating rapidly--and Bayer knows it. It also knows its whopper $14.2 billion deal for Merck & Co.'s consumer business last year isn't going to be enough to keep it on the OTC leaderboard.
Bayer HealthCare has taken full control of the development of CGEN-15001T, an immune checkpoint inhibitor discovered by Compugen. The asset transfer triggered a $7.8 million (€7.1 million) milestone payment by Bayer, bringing the total pocketed by Compugen since it entered into the deal in 2013 up to $25 million.